Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF +2.59%77 3-Year EPS without NRI Growth Rate is 43.70% as of Jun. 2026, which is 529% above its 10-year median of 6.95. GuruFocus rates ALPMF with a GF Scoreâ„¢ of 77/100 and a GF Valueâ„¢ of $15.44 (Fairly Valued). The stock has 5 warning signs investors should review. Among 783 Drug Manufacturers companies, Astellas Pharma ranks better than 85.82% on this metric.
During the past 12 months, Astellas Pharma's average EPS without NRI Growth Rate was 363.10% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 43.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 0.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -10.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Astellas Pharma was 89.70% per year. The lowest was -55.40% per year. And the median was 6.95% per year.
Astellas Pharma (OTCPK:ALPMF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Astellas Pharma 3-Year EPS without NRI Growth Rate Related Terms
ALPMF vs LLY, JNJ, ABBV: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's 3-Year EPS without NRI Growth Rate falls into.
Astellas Pharma 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 43.70% mean?
Astellas Pharma (ALPMF) has a 3-Year EPS without NRI Growth Rate of 43.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Astellas Pharma and its competitors. This is 529% above median its historical median of 6.95. According to the industry distribution chart, Astellas Pharma ranks #111 out of 783 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Astellas Pharma's 3-Year EPS without NRI Growth Rate too high?
Astellas Pharma's current 3-Year EPS without NRI Growth Rate of 43.70% is 529% above median its 10-year median of 6.95. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Astellas Pharma's value of 43.70% is 345.9% above this industry median. Based on the distribution chart, Astellas Pharma ranks #111 out of 783 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's 3-Year EPS without NRI Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #111 out of 783 companies for 3-Year EPS without NRI Growth Rate. This places Astellas Pharma in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Astellas Pharma's value of 43.70% is 345.9% above this benchmark. While the company's 10-year median is 6.95 vs. the industry median of 9.80, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current 3-Year EPS without NRI Growth Rate of 43.70% is 345.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current 3-Year EPS without NRI Growth Rate is 43.70%, which is 529% above median its own 10-year median of 6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $15.44, compared to a current price of $15.85 — trading 2.7% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 43.70%, which is 529% above median its 10-year median of 6.95 and 345.9% above the Drug Manufacturers industry median of 9.80. Astellas Pharma's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current 3-Year EPS without NRI Growth Rate is 43.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of $15.85 is trading 2.7% above its estimated GF Value™ of $15.44.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
3-Year EPS without NRI Growth Rate: 43.70% (529% above median its 10-year median of 6.95)
GF Value™: $15.44 vs. price of $15.85 (2.7% above fair value)
Industry Position: 345.9% above the Drug Manufacturers median (#111 of 783)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score
Get the complete analysis for ALPMF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
